| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $4,136,188 | 10 | 100 |
| SANDERS MACHELLE | director | 0 | $0 | 1 | $68,544 | $-68,544 |
| McKee Amy E | director | 0 | $0 | 1 | $100,285 | $-100,285 |
| HEGGIE THERESA | director | 0 | $0 | 1 | $504,823 | $-504,823 |
| Barnes Alane P | Chief Legal Officer | 0 | $0 | 7 | $3.46M | $-3.46M |
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An …
Over the last 12 months, insiders at BioCryst Pharmaceuticals, Inc. have bought $0 and sold $4.14M worth of BioCryst Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at BioCryst Pharmaceuticals, Inc. have bought $789,891 and sold $2.4M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,861 shares for transaction amount of $49,996 was made by LEVIN ALAN G (director) on 2024‑05‑30.
| 2026-05-18 | Sale | McKee Amy E | director | 11,180 0.0053% | $8.97 | $100,285 | -0.22% | |
| 2026-05-13 | Sale | Barnes Alane P | Chief Legal Officer | 62,500 0.0296% | $9.54 | $596,250 | -6.51% | |
| 2026-03-20 | Sale | HEGGIE THERESA | director | 49,933 0.0248% | $10.11 | $504,823 | -6.60% | |
| 2026-03-16 | Sale | Barnes Alane P | Chief Legal Officer | 150,000 0.0703% | $9.15 | $1.37M | -2.47% | |
| 2025-12-22 | Sale | Barnes Alane P | Chief Legal Officer | 21,773 0.0104% | $7.65 | $166,563 | +14.98% | |
| 2025-12-15 | Sale | Barnes Alane P | Chief Legal Officer | 21,210 0.0101% | $7.65 | $162,257 | +14.89% | |
| 2025-12-03 | Sale | Barnes Alane P | Chief Legal Officer | 19,770 0.0092% | $7.65 | $151,241 | +10.25% | |
| 2025-12-02 | Sale | Barnes Alane P | Chief Legal Officer | 50,906 0.0244% | $7.21 | $367,216 | +20.53% | |
| 2025-12-01 | Sale | Barnes Alane P | Chief Legal Officer | 91,004 0.0431% | $7.10 | $646,511 | +20.97% | |
| 2025-11-13 | Sale | SANDERS MACHELLE | director | 9,600 0.0047% | $7.14 | $68,544 | +24.20% | |
| 2025-08-13 | Sale | HEGGIE THERESA | director | 70,000 0.0333% | $8.51 | $595,868 | -2.81% | |
| 2024-12-13 | Sale | Hutson Nancy J | director | 7,000 0.0034% | $7.54 | $52,780 | +5.71% | |
| 2024-06-24 | Sale | McKee Amy E | director | 8,600 0.0042% | $6.32 | $54,352 | +23.52% | |
| 2024-06-17 | Sale | SANDERS MACHELLE | director | 4,689 0.0021% | $6.00 | $28,134 | +23.88% | |
| 2024-06-14 | Sale | HEGGIE THERESA | director | 6,698 0.0031% | $6.11 | $40,925 | +25.28% | |
| 2024-05-30 | LEVIN ALAN G | director | 7,861 0.0037% | $6.36 | $49,996 | +16.74% | ||
| 2024-05-24 | ASELAGE STEVE | director | 2,500 0.0012% | $6.40 | $16,000 | +24.63% | ||
| 2024-05-20 | Hutson Nancy J | director | 5,000 0.0025% | $6.38 | $31,900 | +24.47% | ||
| 2024-05-20 | MILANO VINCENT | director | 15,000 0.0074% | $6.25 | $93,750 | +24.47% | ||
| 2024-05-14 | Thackray Helen M. | Chief R&D Officer | 30,000 0.0159% | $5.86 | $175,800 | +42.26% |
| Barnes Alane P | Chief Legal Officer | 400703 0.1568% | $3.43M | 2 | 15 | +76.79% |
| HEGGIE THERESA | director | 65352 0.0256% | $560,066.64 | 1 | 3 | +118.24% |
| BAKER FELIX | 10 percent owner | 4832285 1.891% | $41.41M | 1 | 0 | +60.41% |
| Baker Brothers Life Sciences Capital (GP), LLC | 10 percent owner | 3831534 1.4994% | $32.84M | 3 | 3 | +289.09% |
| BAKER BROS. ADVISORS LP | 10 percent owner | 1551387 0.6071% | $13.3M | 11 | 3 | <0.0001% |
| Baker Biotech Capital (GP), LLC | 10 percent owner | 1522015 0.5956% | $13.04M | 3 | 3 | +289.09% |
| Stonehouse Jon P | President & CEO | 1127770 0.4413% | $9.66M | 14 | 8 | +33.41% |
| SHERRILL JOSEPH H JR | director | 492000 0.1925% | $4.22M | 5 | 0 | +141.01% |
| Gayer Charles K | Chief Commercial Officer | 307533 0.1203% | $2.64M | 1 | 1 | +35.35% |
| Babu Yarlagadda S | Chief Discovery Officer | 298541 0.1168% | $2.56M | 1 | 14 | +118.24% |
| Thackray Helen M. | Chief R&D Officer | 272139 0.1065% | $2.33M | 1 | 3 | +42.26% |
| Doyle Anthony | Chief Financial Officer | 266744 0.1044% | $2.29M | 3 | 1 | +65.78% |
| FEATHERINGILL WILLIAM W | director, 10 percent owner | 231538 0.0906% | $1.98M | 3 | 4 | <0.0001% |
| 14159 capital (GP), LLC | 10 percent owner | 120828 0.0473% | $1.04M | 3 | 3 | +289.09% |
| Hutson Nancy J | director | 86638 0.0339% | $742,487.66 | 3 | 4 | +71.35% |
| Baker Bros. Capital (GP), LLC | 10 percent owner | 71997 0.0282% | $617,014.29 | 3 | 3 | +289.09% |
| MILANO VINCENT | director | 66997 0.0262% | $574,164.29 | 2 | 0 | +14.91% |
| BENNETT J CLAUDE | Chief Operating Officer | 65730 0.0257% | $563,306.10 | 2 | 5 | <0.0001% |
| Jensen Peder | director | 60000 0.0235% | $514,200.00 | 4 | 0 | +3.75% |
| Galson Steven K | director | 51551 0.0202% | $441,792.07 | 1 | 0 | +35.35% |
| INGRAM ROBERT ALEXANDER | director | 48088 0.0188% | $412,114.16 | 1 | 0 | +118.24% |
| LEVIN ALAN G | director | 44951 0.0176% | $385,230.07 | 1 | 0 | +16.74% |
| Sniecinski Megan | Chief Business Officer | 45000 0.0176% | $385,650.00 | 1 | 0 | +118.24% |
| Erck Stanley C | director | 40000 0.0157% | $342,800.00 | 1 | 0 | +454.8% |
| Sheridan William P | Chief Medical Officer | 37954 0.0149% | $325,265.78 | 1 | 16 | +240.53% |
| LEE KENNETH B JR | director | 24252 0.0095% | $207,839.64 | 1 | 2 | +118.24% |
| Baker / Tisch Capital (GP), LLC | 10 percent owner | 17241 0.0067% | $147,755.37 | 3 | 3 | +289.09% |
| Grant Stuart | SR VP & CFO | 14717 0.0058% | $126,124.69 | 2 | 10 | +102.99% |
| SANDERS CHARLES A | director | 7000 0.0027% | $59,990.00 | 2 | 0 | <0.0001% |
| ALEXANDER W JAMES | SR. VP, Chief Medical Officer | 3659 0.0014% | $31,357.63 | 2 | 0 | <0.0001% |
| SEIDENBERG BETH C | director | 3000 0.0012% | $25,710.00 | 1 | 0 | <0.0001% |
| DARWIN MICHAEL A | Principal Accounting Officer | 3048 0.0012% | $26,121.36 | 2 | 2 | <0.0001% |
| ASELAGE STEVE | director | 2500 0.001% | $21,425.00 | 4 | 0 | +42.97% |
| RIGGS RANDALL B | Senior VP Business Development | 1928 0.0008% | $16,522.96 | 2 | 1 | <0.0001% |
| Nugent Jonathan M | VP Corp Communications | 508 0.0002% | $4,353.56 | 2 | 1 | <0.0001% |
| ABERCROMBIE GEORGE B | 0 0% | $0 | 2 | 8 | +230.41% |
BioCryst Pharmaceuticals, Inc. (BCRX) | $21,345,882 | 83 | 94.45% | $2.19B |
$47,419,530 | 58 | 17.20% | $1.96B | |
$1,376,668 | 53 | 18.46% | $2.1B | |
$108,353,116 | 49 | 15.41% | $2.17B | |
$586,486,795 | 47 | 4.28% | $2.38B |
| Increased Positions | 194 | +52.15% | 72M | +31.82% |
| Decreased Positions | 169 | -45.43% | 55M | -24.05% |
| New Positions | 82 | New | 35M | New |
| Sold Out Positions | 59 | Sold Out | 25M | Sold Out |
| Total Postitions | 397 | +6.72% | 245M | +7.77% |
| Vanguard Group Inc | $163,432.00 | 10.33% | 21.79M | +1M | +6.07% | 2025-09-30 |
| Blackrock, Inc. | $159,344.00 | 10.07% | 21.25M | -179,973 | -0.84% | 2025-09-30 |
| Deerfield Management Company, L.P. | $91,268.00 | 5.77% | 12.17M | +7M | +159.36% | 2025-09-30 |
| State Street Corp | $73,556.00 | 4.65% | 9.81M | +1M | +15.31% | 2025-09-30 |
| Kynam Capital Management, Lp | $70,427.00 | 4.45% | 9.39M | +926,528 | +10.95% | 2025-09-30 |
| Ubs Group Ag | $44,758.00 | 2.83% | 5.97M | +353,086 | +6.29% | 2025-09-30 |
| Alkeon Capital Management Llc | $40,980.00 | 2.59% | 5.46M | -250,000 | -4.38% | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $39,195.00 | 2.48% | 5.23M | +947,431 | +22.14% | 2025-09-30 |
| Morgan Stanley | $39,022.00 | 2.47% | 5.2M | -126,720 | -2.38% | 2025-09-30 |
| Geode Capital Management, Llc | $37,892.00 | 2.39% | 5.05M | -2,303 | -0.05% | 2025-09-30 |